Bruker Daltonics and Queensland Institute of Medical Research Expand Collaboration with Installation of maXis(TM) UHR-TOFBILLERICA, Mass. & BRISBANE, QLD, Jan 05, 2009 (BUSINESS WIRE) -- Bruker Daltonics and the Queensland Institute of Medical Research (QIMR)
announced today the installation of the first maXis(TM) Ultra-High
Resolution Time-Of-Flight (UHR-TOF) mass spectrometer in Australasia,
thereby further strengthening the collaboration between Bruker and one
of the premier medical research institutes in Australia.
maXis is the only instrument available today that uniquely
combines the previously incompatible trends in modern mass spectrometry
of ultra-high resolution and very fast chromatographic separations.
Exceptional mass accuracy, high resolution and sensitivity are
maintained even when coupled to the fastest liquid chromatography
systems. maXis has already been proven as an exceptional
tool in quantitative proteomics, peptide and intact protein analysis as
well as on-the-fly unambiguous small molecule identification using the
unique Smartformula(TM) 3D method.
"Bruker is delighted to further strengthen the collaborative
relationship we have developed with Professor Gorman and QIMR. The
installation of maXis, the first in Australasia, offers a
major opportunity for us to co-develop the advanced methodologies
required for the wide range of applications undertaken at QIMR's Protein
Discovery Centre (PDC)," stated Clive Seymour, Executive Vice President
of Bruker Daltonics.
"The installation of maXis will allow us to
collaborate more extensively with Bruker, particularly in the
development of ETD methodologies for the study of post-translational
modifications on this exciting new platform, and represents a quantum
leap in MS capability at QIMR," commented Professor Jeff Gorman,
Director of the PDC. He continued: "maXis completes the
stable of high resolution mass spectrometers within the facility and is
a brand new technology advancing Australian science at QIMR. maXis
will add significantly to the capability of the PDC to participate in
the Australian government National Collaborative Research Infrastructure
Scheme, funded through Bioplatforms Australia and the Queensland
Government. In particular, it will provide the PDC with the scope to
collaborate more effectively with scientists from QIMR, Australia and
internationally on projects aimed at combating infectious diseases and
cancer."
For more information about Bruker Daltonics and Bruker Corporation
(NASDAQ: BRKR), please visit www.bdal.com
and www.bruker.com.
SOURCE: Bruker Corporation
Bruker Daltonics Inc.
Clive Seymour, +64 21 640 801
Executive Vice President
chs@bdal.com
|
Bruker Corporation
